Accordingly, several studies have reported that uPAR-targeted nanoplatforms modified by the uPA peptide possessed great potential in enhancing tumor targeting, improving delivery efficiency, reducing drug toxicity, and in multimodal synergistic antitumor applications [41–44]. The gene discussed is PLAU; the disease is neoplasm.